All In Biotech

Drug Trial Radar · NCT00662948

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Dec 2008

Primary completion

Oct 2014

Study completion Oct 30, 2017

Sponsor

Lead sponsor
PETHEMA FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GELCAB; Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
First posted
Apr 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

After conventional induction treatment with R-CHOP (Rituximab, cyclophosphamide, adriamycin, vincristine and prednisone) the patients are randomized to: A: Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg B: Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months

Conditions

  • Lymphoma

Interventions

  • RituximabDrug

    375 mg/m2 every 8 weeks during 24 months

  • Ibritumomab tiuxetanDrug

    One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 2 years

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Juan Canalejo

    A Coruña, Spain

  • Hospital de Alcorcón

    Alcorcón, Spain

  • Hospital germans Trias i Pujol

    Badalona, Spain

  • Hospital Clínic

    Barcelona, Spain

  • Hospital de la santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Doce de Octubre

    Madrid, Spain

  • Hospital La Paz

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • MD Anderson

    Madrid, Spain

  • Hospital Virgen de la Arrixaca

    Murcia, Spain

  • Hospital son Dureta

    Palma de Mallorca, Spain

  • Hospital Clínico

    Salamanca, Spain

  • Hospital de Donostia

    San Sebastián, Spain

  • Hoaspital Marqués de Valdecilla

    Santander, Spain

  • Hospital Clínico Universitario

    Santiago de Compostela, Spain

  • Hospital Clínico

    Valencia, Spain

  • Hospital Dr Pesset

    Valencia, Spain

  • Hospital General

    Valencia, Spain

  • Hospital La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.